Home >> General Pharmaceuticals >> Housing >> Food & Beverage >>

Chemotherapy Induced Neutropenia - Pipeline Review, H1 2015

Published: Jan-2015 | Format: PDF | Global Markets Direct | Number of pages: 109 | Code: MRS - 18402

 

Global Markets Directs, Chemotherapy Induced Neutropenia Pipeline Review, H1 2015, provides an overview of the Chemotherapy Induced Neutropenias therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chemotherapy Induced Neutropenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chemotherapy Induced Neutropenia and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Neutropenia
The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in the therapeutics development for Chemotherapy Induced Neutropenia and enlists all their major and minor projects
The report summarizes all the dormant and discontinued pipeline projects 
A review of the Chemotherapy Induced Neutropenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
A detailed assessment of monotherapy and combination therapy pipeline projects
Coverage of the Chemotherapy Induced Neutropenia pipeline on the basis of target, MoA, route of administration and molecule type
Latest news and deals relating related to pipeline products

Reasons to buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop strategic initiatives by understanding the focus areas of leading companies
Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Neutropenia
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Neutropenia pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline 

Table Of Content


Table of Contents 2
List of Tables 7
List of Figures 8

Introduction 9
Global Markets Direct Report Coverage 9
Chemotherapy Induced Neutropenia Overview 10
Therapeutics Development 11
Pipeline Products for Chemotherapy Induced Neutropenia - Overview 11
Pipeline Products for Chemotherapy Induced Neutropenia - Comparative Analysis 12
Chemotherapy Induced Neutropenia - Therapeutics under Development by Companies 13
Chemotherapy Induced Neutropenia - Therapeutics under Investigation by Universities/Institutes 16
Chemotherapy Induced Neutropenia - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Chemotherapy Induced Neutropenia - Products under Development by Companies 21
Chemotherapy Induced Neutropenia - Products under Investigation by Universities/Institutes 24
Chemotherapy Induced Neutropenia - Companies Involved in Therapeutics Development 25
Bio-Ker s.r.l 25
Biogenomics Limited 26
Bolder Biotechnology, Inc. 27
Cellerant Therapeutics, Inc. 28
Coherus BioSciences, Inc. 29
Dong-A Socio Group 30
Generon (Shanghai) Corporation Ltd. 31
Hanmi Pharmaceuticals, Co. Ltd. 32
Io Therapeutics, Inc. 33
Mycenax Biotech Inc. 34
Myelo Therapeutics GmbH 35
Octapharma AG 36
PharmaEssentia Corporation 37
Reliance Life Sciences Pvt. Ltd. 38
Richter Gedeon Nyrt. 39
Sandoz Inc. 40
Sandoz International GmbH 41
Teva Pharmaceutical Industries Limited 42
UAB Profarma 43
USV Limited 44
Welichem Biotech Inc. 45
XBiotech USA, Inc. 46
Chemotherapy Induced Neutropenia - Therapeutics Assessment 47
Assessment by Monotherapy Products 47
Assessment by Target 48
Assessment by Mechanism of Action 50
Assessment by Route of Administration 52
Assessment by Molecule Type 54
Drug Profiles 56
balugrastim - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
BBT-007 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
BBT-015 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
BBT-018 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
BK-0026 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Cell Therapy for Chemotherapy Induced Neutropenia - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
F-627 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
filgrastim - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
filgrastim - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
filgrastim - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
filgrastim - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
filgrastim - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
filgrastim - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
filgrastim - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
filgrastim (recombinant) - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
GW-003 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
HM-10460A - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
IRX-4310 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
lipegfilgrastim - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Myelo-001 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
pegfilgrastim - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
pegfilgrastim - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
pegfilgrastim - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
pegfilgrastim - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
pegfilgrastim - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
pegfilgrastim - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
pegfilgrastim - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
pegfilgrastim - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Recombinant Protein for Chemotherapy Induced Neutropenia - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
romyelocel-L - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
TXA-302 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
WBI-2100 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
Chemotherapy Induced Neutropenia - Recent Pipeline Updates 92
Chemotherapy Induced Neutropenia - Dormant Projects 98
Chemotherapy Induced Neutropenia - Discontinued Products 100
Chemotherapy Induced Neutropenia - Product Development Milestones 101
Featured News & Press Releases 101
Dec 08, 2014: Generon Presents the Global Phase II Study Results for F-627 (benegrastim) at the American Society of Hematology 56th Annual Meeting at San Francisco 101
Sep 09, 2014: Spectrum Pharmaceuticals Makes Decision to Advance SPI-2012, a Novel Long-Acting GCSF, to Phase 3 Due to Positive Phase 2 Results in its Collaboration Program with Hanmi Pharm 102
May 28, 2014: Spectrum Pharmaceuticals Completes Enrollment in Phase 2 Trial of SPI-2012 - A Novel Long-Acting Granulocyte Colony Stimulating Factor to Treat Chemotherapy-induced Neutropenia 103
Mar 25, 2014: Sandoz receives approval for biosimilar filgrastim in Japan 103
Nov 18, 2013: Teva announces Launch of LONQUEX Injection 104
Jul 22, 2013: Zarzio overtakes Neupogen and Granocyte to become most prescribed daily G-CSF in Europe 105
Jun 03, 2013: Teva's Lonquex Receives Positive Opinion From CHMP For Reduction Of Chemotherapy-induced Neutropenia 105
Apr 25, 2013: Sandoz Files For Marketing Authorization Of Biosimilar Filgrastim In Japan 106
Apr 08, 2013: Spectrum Pharma Initiates Phase II Study Of Long-acting GCSF Drug Candidate SPI-2012 For Treatment Of Chemotherapy-induced Neutropenia 106
Jan 07, 2013: Generon Initiates Phase I/II Clinical Trial Of F-627 For Treatment Of Breast Cancer In China 107
 

Appendix 108
Methodology 108
Coverage 108
Secondary Research 108
Primary Research 108
Expert Panel Validation 108
Contact Us 109
Disclaimer 109


List of Tables

Number of Products under Development for Chemotherapy Induced Neutropenia, H1 2015 11
Number of Products under Development for Chemotherapy Induced Neutropenia - Comparative Analysis, H1 2015 12
Number of Products under Development by Companies, H1 2015 14
Number of Products under Development by Companies, H1 2015 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H1 2015 16
Comparative Analysis by Late Stage Development, H1 2015 17
Comparative Analysis by Clinical Stage Development, H1 2015 18
Comparative Analysis by Early Stage Development, H1 2015 19
Comparative Analysis by Unknown Stage Development, H1 2015 20
Products under Development by Companies, H1 2015 21
Products under Development by Companies, H1 2015 (Contd..1) 22
Products under Development by Companies, H1 2015 (Contd..2) 23
Products under Investigation by Universities/Institutes, H1 2015 24
Chemotherapy Induced Neutropenia - Pipeline by Bio-Ker s.r.l, H1 2015 25
Chemotherapy Induced Neutropenia - Pipeline by Biogenomics Limited, H1 2015 26
Chemotherapy Induced Neutropenia - Pipeline by Bolder Biotechnology, Inc., H1 2015 27
Chemotherapy Induced Neutropenia - Pipeline by Cellerant Therapeutics, Inc., H1 2015 28
Chemotherapy Induced Neutropenia - Pipeline by Coherus BioSciences, Inc., H1 2015 29
Chemotherapy Induced Neutropenia - Pipeline by Dong-A Socio Group, H1 2015 30
Chemotherapy Induced Neutropenia - Pipeline by Generon (Shanghai) Corporation Ltd., H1 2015 31
Chemotherapy Induced Neutropenia - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015 32
Chemotherapy Induced Neutropenia - Pipeline by Io Therapeutics, Inc., H1 2015 33
Chemotherapy Induced Neutropenia - Pipeline by Mycenax Biotech Inc., H1 2015 34
Chemotherapy Induced Neutropenia - Pipeline by Myelo Therapeutics GmbH, H1 2015 35
Chemotherapy Induced Neutropenia - Pipeline by Octapharma AG, H1 2015 36
Chemotherapy Induced Neutropenia - Pipeline by PharmaEssentia Corporation, H1 2015 37
Chemotherapy Induced Neutropenia - Pipeline by Reliance Life Sciences Pvt. Ltd., H1 2015 38
Chemotherapy Induced Neutropenia - Pipeline by Richter Gedeon Nyrt., H1 2015 39
Chemotherapy Induced Neutropenia - Pipeline by Sandoz Inc., H1 2015 40
Chemotherapy Induced Neutropenia - Pipeline by Sandoz International GmbH, H1 2015 41
Chemotherapy Induced Neutropenia - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 42
Chemotherapy Induced Neutropenia - Pipeline by UAB Profarma, H1 2015 43
Chemotherapy Induced Neutropenia - Pipeline by USV Limited, H1 2015 44
Chemotherapy Induced Neutropenia - Pipeline by Welichem Biotech Inc., H1 2015 45
Chemotherapy Induced Neutropenia - Pipeline by XBiotech USA, Inc., H1 2015 46
Assessment by Monotherapy Products, H1 2015 47
Number of Products by Stage and Target, H1 2015 49
Number of Products by Stage and Mechanism of Action, H1 2015 51
Number of Products by Stage and Route of Administration, H1 2015 53
Number of Products by Stage and Molecule Type, H1 2015 55
Chemotherapy Induced Neutropenia Therapeutics - Recent Pipeline Updates, H1 2015 92
Chemotherapy Induced Neutropenia - Dormant Projects, H1 2015 98
Chemotherapy Induced Neutropenia - Dormant Projects (Contd..1), H1 2015 99
Chemotherapy Induced Neutropenia - Discontinued Products, H1 2015 100

List of Figures

Number of Products under Development for Chemotherapy Induced Neutropenia, H1 2015 11
Number of Products under Development for Chemotherapy Induced Neutropenia - Comparative Analysis, H1 2015 12
Number of Products under Development by Companies, H1 2015 13
Comparative Analysis by Late Stage Development, H1 2015 17
Comparative Analysis by Clinical Stage Development, H1 2015 18
Comparative Analysis by Early Stage Products, H1 2015 19
Assessment by Monotherapy Products, H1 2015 47
Number of Products by Top 10 Targets, H1 2015 48
Number of Products by Stage and Top 10 Targets, H1 2015 48
Number of Products by Top 10 Mechanism of Actions, H1 2015 50
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 51
Number of Products by Top 10 Routes of Administration, H1 2015 52
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 53
Number of Products by Top 10 Molecule Types, H1 2015 54
Number of Products by Stage and Top 10 Molecule Types, H1 2015 55

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2000 View Pricing